vs
Side-by-side financial comparison of HACKETT GROUP, INC. (HCKT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
HACKETT GROUP, INC. is the larger business by last-quarter revenue ($68.8M vs $60.1M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). HACKETT GROUP, INC. runs the higher net margin — 6.2% vs -92.6%, a 98.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -11.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -5.9%).
Hackett Limited is a British multi-channel retailer of clothing for men and boys, with a broad range of apparel and accessories. It was founded in 1983 in London, England. As of June 2019, the company had 160 stores globally, with its flagship store at 14 Savile Row in London. It is owned by both Lebanese holding company M1 Group and American L Capital Asia
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
HCKT vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $68.8M | $60.1M |
| Net Profit | $4.3M | $-55.6M |
| Gross Margin | 70.8% | 88.1% |
| Operating Margin | 13.0% | -87.1% |
| Net Margin | 6.2% | -92.6% |
| Revenue YoY | -11.6% | 83.8% |
| Net Profit YoY | 36.2% | — |
| EPS (diluted) | $0.17 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $68.8M | $60.1M | ||
| Q4 25 | $75.8M | $57.3M | ||
| Q3 25 | $73.1M | $51.3M | ||
| Q2 25 | $78.9M | $48.5M | ||
| Q1 25 | $77.9M | $32.7M | ||
| Q4 24 | $79.2M | $41.8M | ||
| Q3 24 | $79.8M | $33.3M | ||
| Q2 24 | $77.7M | $29.1M |
| Q1 26 | $4.3M | $-55.6M | ||
| Q4 25 | $5.6M | $-47.5M | ||
| Q3 25 | $2.5M | $-52.9M | ||
| Q2 25 | $1.7M | $-46.6M | ||
| Q1 25 | $3.1M | $-49.5M | ||
| Q4 24 | $3.6M | $-43.3M | ||
| Q3 24 | $8.6M | $-43.6M | ||
| Q2 24 | $8.7M | $-32.3M |
| Q1 26 | 70.8% | 88.1% | ||
| Q4 25 | 41.7% | 91.6% | ||
| Q3 25 | 40.7% | 89.3% | ||
| Q2 25 | 35.4% | 88.6% | ||
| Q1 25 | 35.8% | 88.8% | ||
| Q4 24 | 39.4% | 90.9% | ||
| Q3 24 | 29.2% | 88.5% | ||
| Q2 24 | 27.5% | 89.9% |
| Q1 26 | 13.0% | -87.1% | ||
| Q4 25 | 12.0% | -82.2% | ||
| Q3 25 | 7.5% | -102.6% | ||
| Q2 25 | 5.8% | -93.4% | ||
| Q1 25 | 5.7% | -143.7% | ||
| Q4 24 | 9.8% | -98.6% | ||
| Q3 24 | 16.0% | -132.0% | ||
| Q2 24 | 16.1% | -139.2% |
| Q1 26 | 6.2% | -92.6% | ||
| Q4 25 | 7.4% | -83.0% | ||
| Q3 25 | 3.5% | -103.1% | ||
| Q2 25 | 2.1% | -96.1% | ||
| Q1 25 | 4.0% | -151.4% | ||
| Q4 24 | 4.5% | -103.6% | ||
| Q3 24 | 10.8% | -131.2% | ||
| Q2 24 | 11.3% | -110.9% |
| Q1 26 | $0.17 | $-0.83 | ||
| Q4 25 | $0.20 | $-0.73 | ||
| Q3 25 | $0.09 | $-0.82 | ||
| Q2 25 | $0.06 | $-0.75 | ||
| Q1 25 | $0.11 | $-0.81 | ||
| Q4 24 | $0.11 | $-0.71 | ||
| Q3 24 | $0.31 | $-0.73 | ||
| Q2 24 | $0.31 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $340.6M |
| Total DebtLower is stronger | $78.8M | — |
| Stockholders' EquityBook value | $66.0M | $122.9M |
| Total Assets | $204.4M | $442.3M |
| Debt / EquityLower = less leverage | 1.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $18.2M | $388.9M | ||
| Q3 25 | $13.9M | $416.1M | ||
| Q2 25 | $10.1M | $291.0M | ||
| Q1 25 | $9.2M | $314.5M | ||
| Q4 24 | $16.4M | $320.6M | ||
| Q3 24 | $10.0M | $298.4M | ||
| Q2 24 | $19.1M | $319.1M |
| Q1 26 | $78.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $66.0M | $122.9M | ||
| Q4 25 | $68.1M | $139.1M | ||
| Q3 25 | $101.6M | $148.8M | ||
| Q2 25 | $119.8M | $-11.9M | ||
| Q1 25 | $114.4M | $18.9M | ||
| Q4 24 | $115.6M | $21.7M | ||
| Q3 24 | $110.9M | $11.2M | ||
| Q2 24 | $102.2M | $39.3M |
| Q1 26 | $204.4M | $442.3M | ||
| Q4 25 | $206.4M | $480.2M | ||
| Q3 25 | $200.7M | $506.9M | ||
| Q2 25 | $200.5M | $372.7M | ||
| Q1 25 | $191.8M | $386.7M | ||
| Q4 24 | $193.3M | $392.3M | ||
| Q3 24 | $190.8M | $363.6M | ||
| Q2 24 | $187.5M | $381.8M |
| Q1 26 | 1.19× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCKT
| Revenue before reimbursements | $36.4M | 53% |
| Other | $32.0M | 47% |
| Reimbursements | $405.0K | 1% |
RYTM
Segment breakdown not available.
